- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Goflikicept PREVENTS recurrence and MAINTAINS remission in idiopathic recurrent pericarditis patients
An Original Investigation by Dr Valentina Yu. Myachikova, published in the Journal of the American College of Cardiology, has demonstrated the benefits of Goflikicept in idiopathic recurrent pericarditis. This anti-cytokine biologic prevents recurrence and maintains IRP remission with a favourable risk-benefit ratio, as described in the study.It is already known that IRP is a...
An Original Investigation by Dr Valentina Yu. Myachikova, published in the Journal of the American College of Cardiology, has demonstrated the benefits of Goflikicept in idiopathic recurrent pericarditis. This anti-cytokine biologic prevents recurrence and maintains IRP remission with a favourable risk-benefit ratio, as described in the study.
It is already known that IRP is a rare autoinflammatory disease. Interleukin (IL)-1α and IL-1β are the pivotal cytokines in the pathophysiology of acute pericarditis. These are involved in its recurrence also.
In the present study, the team created a phase II/III study with a new IL-1 inhibitor—goflikicept in IRP and evaluated its safety and efficacy in treating IRP patients in their 2-centre open-label study.
The study had four periods: screening, run-in, randomized withdrawal, and follow-up.
The study results could be summarised as follows:
- Twenty-two patients were enrolled, and 20 were randomized.
- During the run-in period, results demonstrated a reduction of C-reactive protein level accompanied by a reduction of chest pain and pericardial effusion compared to baseline.
- There was a Recurrence of pericarditis in 9/10 patients in the placebo group.
- Researchers reported no recurrence events in the goflikicept group within 24 weeks following randomization.
- A total of 122 adverse events were reported in 21 patients (95.5%), with no deaths and no new safety signals identified for goflikicept.
They said goflikicept prevents recurrences and maintains IRP remission with a favourable risk-benefit ratio. Goflikicept reduced the risk of recurrence compared with the placebo.
Further reading:
BDS, MDS in Periodontics and Implantology
Dr. Aditi Yadav is a BDS, MDS in Periodontics and Implantology. She has a clinical experience of 5 years as a laser dental surgeon. She also has a Diploma in clinical research and pharmacovigilance and is a Certified data scientist. She is currently working as a content developer in e-health services. Dr. Yadav has a keen interest in Medical Journalism and is actively involved in Medical Research writing.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751